Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Clin Neurosci. 2020 Nov;81:353-366. doi: 10.1016/j.jocn.2020.09.073. Epub 2020 Oct 23.
Pseudarthrosis continues to affect a nontrivial proportion of spine fusion patients. Given its ties to poorer patient outcomes and high reoperation rates, there remains great interest in interventions aimed at reducing the rates of nonunion. Recently, silicate-substituted calcium phosphate (SiCaP) bone grafts have been suggested to improve fusion rates, yet there exists no systematic review of the body of evidence for SiCaP grafts. Here, we present the first such review along with a meta-analysis of the effect of SiCaP bone grafts on fusion rates. Using the PubMed, Embase, and Web of Science databases, we queried the English-language literature for all studies examining the effect of SiCaPs on spinal fusion. Primary endpoints were: 1) radiographic fusion rate at last follow-up and 2) postoperative improvements in Visual Analog Scale (VAS) pain scores and Oswestry Disability Index (ODI) at last follow-up. Meta-analyses were performed for each endpoint using random effects. Ten articles (694 patients treated with SiCaP bone grafts) were included. Among SiCaP-treated patients, 93% achieved radiographic fusion (range: 79-100%), with comparable rates across subgroups. Meta-analysis of the three randomized controlled trials demonstrated no difference in fusion rates between SiCaP-treated patients and patients receiving grafts with recombinant human bone morphogenetic protein-2 (rhBMP-2) (OR: 1.11; p = 0.83). Patients treated with SiCaP bone grafts experienced significant improvements in VAS back pain (-3.3 points), VAS leg pain (-4.8 points), and ODI (-31.6 points) by last follow-up (p < 0.001 for each). Additional high-quality research is needed to evaluate the relative cost-effectiveness of SiCaP bone grafts in spinal fusion.
假关节仍然会影响相当一部分脊柱融合患者。鉴于其与较差的患者预后和高再手术率有关,人们仍然对旨在降低非融合率的干预措施非常感兴趣。最近,硅酸钙取代的磷酸钙(SiCaP)骨移植物被认为可以提高融合率,但目前还没有关于 SiCaP 移植物证据的系统评价。在这里,我们提出了第一个这样的综述,并对 SiCaP 骨移植物对融合率的影响进行了荟萃分析。我们使用 PubMed、Embase 和 Web of Science 数据库,检索了所有研究 SiCaPs 对脊柱融合影响的英文文献。主要终点是:1)最后随访时的放射融合率和 2)最后随访时视觉模拟量表(VAS)疼痛评分和 Oswestry 残疾指数(ODI)的术后改善。使用随机效应对每个终点进行荟萃分析。共纳入 10 篇文章(694 例接受 SiCaP 骨移植物治疗的患者)。在接受 SiCaP 治疗的患者中,93%的患者达到了影像学融合(范围:79-100%),亚组间的融合率相似。对三项随机对照试验的荟萃分析表明,接受 SiCaP 治疗的患者与接受重组人骨形态发生蛋白-2(rhBMP-2)治疗的患者之间融合率没有差异(OR:1.11;p=0.83)。接受 SiCaP 骨移植物治疗的患者在最后一次随访时 VAS 背痛(-3.3 分)、VAS 腿痛(-4.8 分)和 ODI(-31.6 分)均有显著改善(p<0.001)。需要更多高质量的研究来评估 SiCaP 骨移植物在脊柱融合中的相对成本效益。